Introduction
============

Iron-based magnetic nanoparticles (NPs) such as magnetite (Fe~3~O~4~) have been studied in detail due to their unique properties, such as stability over time, biocompatibility, and sensitivity to magnetic field.[@b1-ijn-13-079]--[@b3-ijn-13-079] They can potentially be used as magnetic targeted drug delivery carriers and magnetic resonance imaging contrast agents due to their high saturation magnetization, low toxicity, and biocompatibility.[@b4-ijn-13-079] The magnetic properties of Fe~3~O~4~ NPs are attributed to their size and size distribution, which, in turn, is dependent on the route of synthesis.

Therefore, in this study, an attempt was made to synthesize Fe~3~O~4~ NPs using a safe-by-design approach by the coprecipitation method. Polyethylene glycol (PEG) was used as surfactant to control the particle size and narrow size distribution. The biocompatibility of Fe~3~O~4~ NPs was evaluated by cytotoxicity assays and cell cycle analysis in the human breast adenocarcinoma cell line (MCF-7).

Materials and methods
=====================

Materials
---------

Ferric chloride hexahydrate and ferrous sulfate were purchased from SD-Fine-Chem. Ltd, Mumbai, India. Ployetheleneglycol (PEG-6000), dimethylesulphoxide, sodium hydroxide (NaOH), minimum essential medium eagle, phosphate-buffered saline, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and antibiotic-antimycotic solution were purchased from HiMedia Laboratories Pvt. Ltd., (Mumbai, India). The MCF-7 cell line was purchased from the National Centre for Cell Sciences, Pune, India.

Fe~3~O~4~ NP synthesis
----------------------

The preparation of Fe~3~O~4~ NPs was performed by a chemical coprecipitation method of Fe^2+^ and Fe^3+^ ions (1:2 molar ratios) by the addition of NaOH.[@b5-ijn-13-079] A total volume of 15 mL of 0.25 M Fe^2+^ and 0.5 M Fe^3+^ solutions were prepared in deionized water. PEG was then added and the temperature slowly risen up to 80°C. During the initial 2 minutes of the reaction, NaOH was added to achieve a pH of 10. The reaction was allowed to continue on a magnetic stirrer for 2 hours. Thereafter, the suspension was centrifuged and washed several times with deionized water to lower the pH to 7. Finally, the particles were suspended in 10 mL of dimethylesulphoxide.

Characterization of Fe~3~O~4~ NPs
---------------------------------

One milliliter of the stock suspension of Fe~3~O~4~ NPs was diluted in 10 mL complete minimum essential medium eagle. The hydrodynamic size and zeta potential were determined using Zetasizer Nano ZS.

Cytotoxicity assessment
-----------------------

The cytotoxic potential of Fe~3~O~4~ NPs was assessed in MCF-7 cells after 6 and 24 hours of treatment using MTT and neutral red uptake (NRU) assays as described by Mosmann[@b6-ijn-13-079] and Borenfreund and Puerner, respectively.[@b7-ijn-13-079]

Cellular internalization of NPs
-------------------------------

The internalization of Fe~3~O~4~ NPs in MCF-7 cells was assessed according to the method described in our earlier study.[@b8-ijn-13-079]

Cell cycle analysis
-------------------

The effect of Fe~3~O~4~ NPs on cell cycle was assessed according to the method described in our earlier study.[@b8-ijn-13-079]

Results and discussion
======================

The mean hydrodynamic size and zeta potential of synthesized Fe~3~O~4~ NPs were 98.19±1.0 nm and 36±2 mV, respectively. Flow cytometric analysis revealed a significant (*P*\<0.05) increase in the internalization of Fe~3~O~4~ NPs in MCF-7 cells after 24 hours exposure at the two higher concentrations, as evident by an increase in the side scatter intensity ([Figure 1](#f1-ijn-13-079){ref-type="fig"}).

In the cytotoxicity assays, namely NRU and MTT, Fe~3~O~4~ NPs were found to be biocompatible as there was no significant increase in the NRU (88% at concentration 150 μM/mL) and a reduction (96%) in the mitochondrial succinate dehydrogenase activity was observed at the highest concentration after 24-hour exposure ([Figures 2A and B](#f2-ijn-13-079){ref-type="fig"}).

Additionally, no change in cell cycle progression was observed in Fe~3~O~4~ NPs-treated MCF-7 cells, after 24-hour exposure ([Figure 3](#f3-ijn-13-079){ref-type="fig"}).

Conclusion
==========

Our results demonstrated that Fe~3~O~4~ NPs synthesized using the safe-by-design approach showed no adverse effect on cells, as assessed by cytotoxicity assays and cell cycle analysis in MCF-7 cells, even though they are significantly internalized. Therefore, these NPs have a potential to be used as a carrier for targeted drug delivery.
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![Internalization of Fe~3~O~4~ NPs in MCF-7 cells using flow cytometry.\
**Notes:** Data are expressed as mean ± standard error of the mean from three independent experiments. \**P*\<0.05, when compared with control.\
**Abbreviations:** NPs, nanoparticles; MCF-7, human breast adenocarcinoma cell line.](ijn-13-079Fig1){#f1-ijn-13-079}

![Cytotoxicity of Fe~3~O~4~ NPs in MCF-7 cells. (**A**) NR uptake (%); (**B**) MTT reduction (%).\
**Notes:** The viability of the control cells was considered as 100%. Data are expressed as mean ± standard error of the mean from three independent experiments.\
**Abbreviations:** NPs, nanoparticles; MCF-7, human breast adenocarcinoma cell line; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NR, neutral red.](ijn-13-079Fig2){#f2-ijn-13-079}

![Effect of Fe~3~O~4~ NPs on cell cycle progression in MCF-7 cells (**A**) control (**B**--**E**) cells treated with different concentration of Fe~3~O~4~ NPs and (**F**) cells treated with 4 mM EMS.\
**Abbreviations:** EMS, ethylmethane sulfonate; NPs, nanoparticles; MCF-7, human breast adenocarcinoma cell line.](ijn-13-079Fig3){#f3-ijn-13-079}
